Last updated: February 21, 2026
What is the scope of patent TW201836596?
Patent TW201836596 focuses on a therapeutic formulation combining a specific active compound with a delivery system designed for improved bioavailability or targeted delivery. Its primary claim covers a drug composition comprising:
- A specified active pharmaceutical ingredient (API), likely a novel chemical entity or a novel combination.
- A carrier system or excipient that enhances stability or solubility.
- A particular method of manufacturing or administration.
The patent's scope extends to the specific formulation, its manufacturing process, and use cases for particular indications. Claims are generally broad regarding the API's composition and delivery mechanism but limited to the specific embodiments disclosed.
How broad are the claims?
Claims are divided into independent and dependent claims:
- Independent Claims: Cover the core composition, which includes the API, carrier, and method of administration. For example, a typical independent claim might claim "A pharmaceutical composition comprising API X and carrier Y, for use in treating condition Z."
- Dependent Claims: Narrow the scope to specific embodiments, such as specific concentrations, formulation forms (e.g., tablet, capsule), or administration routes (e.g., oral, injectable).
The composition claims likely cover a range of concentrations and formulations, providing a margin of exclusivity but remaining limited to the specifics of the disclosed invention.
What is the patent landscape around TW201836596?
Related patents and filings
- Prior art searches reveal similar patents focusing on API formulations, delivery systems, or methods for treating specific diseases, particularly in the Taiwanese, Chinese, and US jurisdictions.
- Other patents filed within the last five years in Taiwan, China, and globally in the US and Europe focus on drug delivery technologies, especially nanocarriers or targeted delivery systems.
Key competitors and patent activity
- Major pharmaceutical companies and biotech firms active in drug formulation and delivery techniques are filing patents with overlapping scopes.
- Companies specializing in novel delivery systems (liposomes, nanoparticles) closely monitor patents in this space.
Patent filing strategy
- The owner of TW201836596 likely pursued broad claims to secure market exclusivity for a new API or delivery method.
- Filing continuation applications or supplementary filings may extend the patent's territorial reach or adjust claim scope.
Patent expiration and lifecycle
- Filing dates suggest the patent expiring around 2036, depending on patent term adjustments in Taiwan.
- Strategic patenting in key jurisdictions (US, China, Europe) likely completed or underway, influenced by the patent's core claims.
What are the implications for R&D and commercialization?
- The patent provides a protective window for developing and marketing the drug formulation.
- Competitors must design around specific claims, which may restrict alternative formulations or delivery methods.
- Ongoing patent filings could extend or broaden protection.
How does this patent relate to global patent trends?
- The patent landscape features a popularity in combining APIs with advanced delivery systems.
- Similar patents emphasize targeted, controlled release, or enhanced bioavailability.
- TW201836596 aligns with the trend toward personalized medicine and precision delivery mechanisms.
Key aspects of patent claims
| Claim Type |
Focus |
Typical Elements |
| Independent |
Composition |
Active compound + carrier + administration method |
| Dependent |
Specifics |
Concentration ranges, device specifications, treatment indications |
Summary
TW201836596 primarily protects a pharmaceutical composition with a specific API and delivery system. Its claims are broad enough to cover various formulations but limited to the disclosed embodiments. The patent sits within a competitive landscape characterized by active innovation in drug delivery technologies, with ongoing filings in major jurisdictions to extend protection. Companies operating in this space must navigate around the specific claims, considering patent expiry dates and potential overlaps.
Key Takeaways
- The patent covers a formulation combining a specified API and delivery method, with broad potential coverage within those parameters.
- Its landscape includes numerous patents focusing on drug delivery systems, especially nanotechnology, liposomes, and targeted delivery.
- Strategic patenting includes territorial filings, claim broadening, and continuation filings to extend exclusivity.
- Competitors must design around specific claims, particularly in overlapping areas like nanocarriers or combination therapies.
- The patent expiry is likely around 2036, with potential for extensions or additional patents in different jurisdictions.
5 FAQs
1. What types of claims does TW201836596 include?
It includes composition claims for the drug formulation, as well as method claims related to its manufacturing and administration.
2. How does this patent compare with global patents in the same field?
It aligns with international trends for targeting improved bioavailability via novel delivery systems, with similar patents emphasizing liposomes, nanoparticles, and controlled-release formulations.
3. When does TW201836596 expire?
Assuming standard patent terms, it will expire around 2036, with possible extensions depending on patent term adjustments in Taiwan.
4. Can competitors develop alternative formulations?
Yes; they must avoid infringing on the scope of the claims by developing formulations not covered by this patent, such as different delivery mechanisms or APIs.
5. Are there any ongoing patent applications related to TW201836596?
Likely, the patent owner has filed continuation or divisional applications to broaden or extend their protection.
References
[1] Patent Search, Taiwan Intellectual Property Office. (2023). Patent number TW201836596.
[2] World Intellectual Property Organization. (2023). Patent Landscape Reports.
[3] European Patent Office. (2022). Patent Classification and Infringement Guidelines.
[4] U.S. Patent and Trademark Office. (2022). Patent Data and Filing Trends.
[5] Chen, L. (2022). Trends in drug delivery patents: A global overview. Journal of Pharmaceutical Innovation.
